Investigational Drug Details
| Drug ID: | D497 |
| Drug Name: | Namodenoson |
| Synonyms: | CF102; 2-Cl-IB-MECA; CF102 |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 163042-96-4 |
| Repositioning for NAFLD: | No |
| SMILES: | CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O |
| Structure: |
|
| InChiKey: | IPSYPUKKXMNCNQ-PFHKOEEOSA-N |
| Molecular Weight: | 544.74 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | A3 adenosine receptor agonist |
| Therapeutic Category: | Anti-inflammatory |
| Clinical Trial Progress: | Phase 2 on-going (NCT04697810) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0208 | NCT04697810 | Phase 2 | Recruiting | No Results Available | December 10, 2021 | March 9, 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01639 | 34671996 | Aliment Pharmacol Ther | Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. | Details |
| A09707 | 31638172 | Int J Mol Med | The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice. | Details |
| A49461 | 35744805 | Molecules | Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data. | Details |